Legend Biotech Presents CARVYKTI Data Showing Half of Patients with RRMM Remained Progression-Free and Alive Five Years After a Single Infusion

Legend Biotech reported five-year CARTITUDE-2 Cohort A data showing 50% (10 of 20) of earlier-line relapsed/refractory multiple myeloma patients remained alive and progression-free without further treatment after a single CARVYKTI infusion. Median progression-free survival reached 60.5 months, five-year overall survival was 69.2%, and median overall survival was not reached after 60.7 months of follow-up. The small, single-cohort dataset strengthens the long-term efficacy narrative for CARVYKTI in earlier-line use, although one patient developed acute myeloid leukemia and two deaths occurred since the prior analysis.

Analysis

This is directionally supportive of CARVYKTI's earlier-line value proposition, but the immediate earnings implication is limited: the dataset is small, uncontrolled, and drawn from patients who successfully reached infusion. The investable question is whether long treatment-free intervals shift physician sequencing before competing BCMA options and bispecific antibodies, thereby improving CARVYKTI's share of second-line eligible patients. For LEGN, incremental value accrues disproportionately because CARVYKTI remains its principal commercial asset; for JNJ, the same outcome is strategically useful but immaterial to consolidated EPS.

The second-order bottleneck is operational rather than clinical. Earlier-line penetration requires referral, leukapheresis, manufacturing-slot availability, bridging-therapy management, and payer acceptance of a high upfront cost versus recurring regimens. If capacity and vein-to-vein times improve, CAR-T can cannibalize chronic myeloma drug spend—including JNJ's own bispecific franchise—and pressure BMY's ABECMA positioning; if they do not, durable efficacy will not translate proportionately into treated-patient volume.

Near term, expect modest LEGN multiple support around conference follow-through rather than a material estimate revision. Over 1-3 months, the relevant catalysts are CARVYKTI quarterly sales, manufacturing capacity/utilization, and evidence of reduced dropout before infusion; over 6-18 months, payer policy and broader earlier-line label expansion determine whether the market can underwrite a structurally higher peak-sales base. The key falsifiers are decelerating CARVYKTI revenue despite capacity additions, worsening treatment-related mortality/infection disclosures, or competing BCMA/bispecific data that narrows the durability gap.

Key Decisions for Investors

• Maintain or initiate a modest long LEGN position on post-data weakness, with a 6-12 month horizon; thesis requires CARVYKTI sales growth and evidence that manufacturing capacity converts into infusions, not merely demand. Size conservatively given single-product concentration and the non-randomized n=20 evidence base.
• Use JNJ as the lower-volatility way to express continued CARVYKTI adoption only for portfolios requiring large-cap healthcare exposure; do not expect this update alone to move JNJ estimates materially.
• Watch a relative-value long LEGN / short BMY basket only after confirming ABECMA share loss or weaker BMY cell-therapy guidance; BMY's diversification makes a clean immediate pair trade premature.
• Set a downside alert around any regulatory or label-safety action tied to infection, secondary malignancy, or delayed neurologic events. Such an event would impair earlier-line adoption disproportionately and would invalidate the LEGN growth-multiple thesis faster than efficacy updates can repair it.